Spero Therapeutics (SPRO) Profit After Tax (2016 - 2026)

Spero Therapeutics has reported Profit After Tax for 11 years, with the latest figure at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 48.05% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (up 121.78% YoY), and the FY2025 full-year result was $8.6 million, up 112.5% from the prior year.
• Profit After Tax for Q1 2026 stood at -$7.2 million, down from $31.5 million in the prior quarter.
• The five-year high for Profit After Tax was $51.2 million in Q4 2023, with the low at -$32.8 million in Q1 2022.
• Historically, Profit After Tax has averaged -$5.3 million across 5 years, with a median of -$11.9 million in 2023.
• Annual changes were most pronounced in 2024 — Profit After Tax slumped 434.38% — and 2025, when it surged 250.58%.
• Spero Therapeutics' Profit After Tax stood at $26.8 million in 2022, then jumped by 91.27% to $51.2 million in 2023, then sank by 140.82% to -$20.9 million in 2024, then surged by 250.58% to $31.5 million in 2025, then tumbled by 122.89% to -$7.2 million in 2026.
• The last three Profit After Tax figures came in at -$7.2 million (Q1 2026), $31.5 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.